Cholangiocarcinoma (CCA) is an aggressive cancer of the bile ducts that is usually diagnosed at an advanced stage. Incidence rates are increasing and approximately 20,000 people will be diagnosed with CCA in the next 12 months globally. At Taiho Oncology, we have an unwavering commitment to improving the lives of patients with cancer through our daily pursuit of novel therapies across multiple cancer types, including our relentless dedication to advancing care in CCA. Find out more about how we are making the human connection through our work. #TaihoOncology #Oncology #TaihoCares
Taiho Oncology, Inc.’s Post
More Relevant Posts
-
The approval was based on findings from the open-label, single-arm PHAROS study, which included 98 patients with metastatic BRAF V600E-mutated NSCLC cancer. Among the 59 treatment-naive patients, 75% achieved an objective response. Among the 39 previously treated patients, 46% achieved an objective response. The median duration of response was 16.7 months. #fda #approved #oncology #NSCLC #oncology #cancer
-
-
📰 Drug Discovery World featured POLB 001 in the introduction to its Global Cancer Research Guide, which outlined it as an exciting clinical development in addressing cancer immunotherapy-induced CRS, with potential to enable broader use of cancer immunotherapies in an outpatient setting. Click below to read more (starting page 39) https://lnkd.in/gtSZijU9 #POLB #Oncology
-
-
On World Lung Cancer Day, we join the global community in raising awareness about a disease we know all too well. Advancing and accelerating oncology research is core to who we are. See Precision experts in action in an international Phase 1 trial for NSCLC: https://hubs.ly/Q02JJG1h0 #oncology #clinicaltrials #clinicalresearch
-
-
My colleague Alessandra Franceschetti from the Ipsos Oncology Centre of Expertise has written this excellent paper, summarising the latest advances, ongoing challenges and promising potential of targeted therapies for Non-Small Cell Lung Cancer (NSCLC). This is a great overview that highlights how these innovative drugs are set to continue to improve patient outcomes and redefine the landscape of cancer care. Read more by clicking the link below! #Oncology #Ipsos #NSCLC
-
Excellent review article that summarizes the trends in the approvals of oncology therapeutics over the last 2 decades. https://lnkd.in/eyBwryd9 The progress achieved in terms of reduction in mortality across many cancers is indeed enormous. The only thing more fascinating to read would be a comprehensive review article of all the science in the pipeline today that will further revolutionize cancer treatment over the next couple of decades. If someone has come across a good one, please do share. The mission in Cancer is surely beyond 'remission'. #Oncology #MissionCure
-
-
Every moment counts for the nearly 100,000 people in the US living with pancreatic cancer. We are proud of our work to obtain Orphan Drug Designation from the FDA for QN-302 toward a potential novel treatment for pancreatic cancer. Learn more about World Pancreatic Cancer Day here: https://shorturl.at/BZ145 #pancreaticcancer #driventodeliver #clinicaltrials #oncology
-
-
Check out the announcement below from Verismo!
Verismo Therapeutics is thrilled to announce the opening of our second clinical site at MD Anderson Cancer Center for the STAR-101 (NCT05568680) Phase 1 trial that is treating ovarian cancer, mesothelioma and cholangiocarcinoma. This is another leap forward in our mission to help patients that are suffering from cancer. For more information see the full press release: https://lnkd.in/e4SgGzUc #VersimoTherapeutics #SynKIR110 #BestTeamEver #CellTherapy
-
-
🌟 𝗡𝗲𝘄 𝗥𝗲𝗹𝗲𝗮𝘀𝗲: “𝗪𝗵𝗮𝘁’𝘀 𝗡𝗲𝘄 𝗗𝗼𝗰? 𝗶𝗻 𝗚𝗜 𝗖𝗮𝗻𝗰𝗲𝗿” 🌟 Prof Marc Van den Eynde & Prof Eric Van Cutsem unveil new standards in HER2-Positive Gastric Cancer Treatment. This episode delves into the KEYNOTE-811 study's significant findings, demonstrating the enhanced efficacy and safety of combining pembrolizumab with trastuzumab and chemotherapy for HER2-positive gastric cancer patients. The study marks a milestone in cancer treatment, offering a beacon of hope for patients and setting new benchmarks for future therapies. 👇 Watch the full video link in the comments! #MediMix #HER2Positive #GastricCancer #OncologyInnovation
-
Exciting Updates from ASCO 2024 on Bladder Cancer! Dr Jérémy Blanc from the Institut Jules Bordet, Brussels selected highlights on bladder cancer from ASCO24. - ULTMA Trial: The efficacy of the modified FOLFIRINOX regimen in advanced urachal cancer. - Enfortumab vedotin: - Patient-reported outcomes from the EV-302 trial - Impact of EV plasma exposure on outcomes Discover these updates.👇 For all ASCO 2024 videos, find the link in the comments! #BladderCancer #ASCO2024 #Oncology #MediMix #ClinicalTrials
-
🚀 Live from ASCO 2024! Our latest Daily Highlight focuses on groundbreaking advancements in GI cancer research. Discover key studies on new treatments for gastric cancer, pancreatic cancer, hepatocellular cancer, and GEP-NETs, presented by Prof Alain Hendlisz. Discover these updates.👇 For all ASCO 2024 videos, find the link in the comments! #MediMix #ASCO2024 #GICancer #OncologyInnovation
